Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06689956
Status
Recruiting
Apply to this trial

Conditions

  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
  • Stage IA1 Endometrial Cancer FIGO 2023
  • Stage IA2 Endometrial Cancer FIGO 2023

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-Interventional Study

Study Details

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

Key Dates

Start date
Dec 4, 2024
Status verified
Feb 2026
Primary completion
Oct 31, 2029
Completion
Oct 31, 2029

Study Design

Enrollment
212 participants (estimated)

Arms

  • Arm: Observational
    Patients undergo tissue sample collection and have their medical records reviewed on study.

Primary Outcome Measure

Recurrence-free survival (RFS) [ Time Frame: Up to 5 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Clinical Trials Referral Office
[email protected]
855-776-0015
Gretchen E. Glaser, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Christian Dagher
[email protected]
347-798-9213
Nadeem R. Abu-Rustum, MD (PRINCIPAL_INVESTIGATOR)
Houston Methodist HospitalHoustonTexas77030
Behrouz Zand
[email protected]
713-790-3311
Pedro T. Ramirez, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MNMemorial Sloan Kettering Cancer Center· New York, NYHouston Methodist Hospital· Houston, TX

Related Studies